Prolactin and reproductive medicine

Current Opinion in Obstetrics and Gynecology

Volumn 16, Issue 4, 2004, Pages 331-337

  Davis, Julian R E ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Dopamine agonists; Hyperprolactinaemia; Pituitary; Prolactin; Prolactinoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; METOCLOPRAMIDE; PHENOTHIAZINE DERIVATIVE; PROLACTIN; PROLACTIN RECEPTOR; QUINAGOLIDE; DOPAMINE RECEPTOR STIMULATING AGENT;

CLINICAL FEATURE; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG WITHDRAWAL; EVALUATION; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOTHYROIDISM; MENOPAUSE; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; PROLACTINOMA; PSYCHOSIS; REMISSION; REPRODUCTION; REVIEW; TREATMENT INDICATION; VEIN PUNCTURE; BLOOD; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HYPOPHYSIS TUMOR; METABOLISM;

DOPAMINE AGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERPROLACTINEMIA; MENOPAUSE; PITUITARY NEOPLASMS; PREGNANCY; PROLACTIN; PROLACTINOMA;

EID: 16544371176     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000136500.87452.b0     Document Type: Review

References (51)

1. Friesen HG. The discovery of human prolactin: a very personal account. Clin Invest Med 1995; 18:66-72.
2. Forsyth IA, Wallis M. Growth hormone and prolactin - molecular and functional evolution. J Mammary Gland Biol Neoplasia 2002; 7:291-312.
3. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation and clinical aspects. Endocr Rev 1996; 17:639-669.
4. Phelps JY, Bugg EM, Shamblott MJ, et al. Prolactin gene expression in human ovarian follicular cells. Fertil Steril 2003; 79:182-185.
5. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003; 24:1-27. This paper reviews the evidence for a role for prolactin as an autocrine factor that may promote the development or progression of breast cancer.
6. Berwaer M, Martial JA, Davis JRE. Characterization of an upstream promoter directing extrapituitary expression of the human prolactin gene. Mol Endocrinol 1994; 8:635-642.
7. Gellersen B, Kempf R, Telgmann R, DiMattia GE. Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol Endocrinol 1994; 8:356-373.
8. Anderson B, Rosenfeld MG. POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr Rev 2001; 22:2-35.
9. Horseman ND, Yu-Lee L-Y. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr Rev 1994; 15:627-649.
10. Keeler C, Dannies PS, Hodsdon ME. The tertiary structure and backbone dynamics of human prolactin. J Mol Biol 2003; 328:1105-1121.
11. Schroeder MD, Brockman JL, Walker AM, Schuler LA. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology 2003; 144:5300-5307.
12. Wu W, Coss D, Lorenson MY, et al. Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry 2003; 42:7561-7570. Prolactin is phosphorylated in vivo, and a recombinant protein mimics its behaviour. This paper studies how the two isoforms may have different signalling pathways, and thereby exert different effects on target tissues.
13. Corbacho AM, Martinez de la Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002; 173:219-238.
14. Boutin JM, Jolicoeur C, Okamura H, et al. Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. Cell 1988; 53:69-77.
15. Goffin V, Binart N, Touraine P, Kelly PA. Prolactin: the new biology of an old hormone. Annu Rev Physiol 2002; 64:47-67.
16. Goffin V, Binart N, Clement-Lacroix P, et al. From the molecular biology of prolactin and its receptor to the lessons learned from knockout mice models. Genet Anal 1999; 15:189-201.
17. Kelly PA, Binart N, Lucas B, et al. Implications of multiple phenotypes observed in prolactin receptor knockout mice. Front Neuroendocrinol 2001; 22:140-145.
18. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19:225-268.
19. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endo Rev 2001; 22:724-763.
20. Samson WK, Taylor MM, Baker JR. Prolactin-releasing peptides. Regul Pept 2003; 114:1-5. The cloning of a novel prolactin-releasing peptide is reviewed, and the peptides placed in their overall physiological context.
21. Davis JRE, Selby C, Jeffcoate WJ. Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol 1984; 20:427-434.
22. McNeilly AS. Prolactin and the control of gonadotrophin secretion. J Endocrinol 1987; 115:1-5.
23. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol 1998; 48:547-553.
24. Ling C, Svensson L, Oden B, et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 2003; 88:1804-1808. This paper describes new evidence for a direct effect of prolactin on adipocyte function in man, which may have clinical relevance.
25. Reavley S, Fisher AD, Owen D, et al. Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol 1997; 47:343-348.
26. Strachan MW, Teoh WL, Don-Wauchope AC, et al. Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol 2003; 59:339-346. This is a useful survey of the clinical findings in a series of patients with macroprolactin complexes.
27. De Schepper J, Schiettecatte J, Velkeniers B, et al. Clinical and biological characterization of macroprolactinemia with and without prolactin-IgG complexes. Eur J Endocrinol 2003; 149:201-207.
28. Mounier C, Trouillas J, Claustrat B, et al. Macroprolactinaemia associated with prolactin adenoma. Hum Reprod 2003; 18:853-857. This case report demonstrates that the presence of macroprolactin isoforms does not exclude the presence of significant pituitary disease.
29. Chong BW, Kucharczyk W, Singer W, George S. Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas. Am J Neuroradiol 1994; 49:126-129.
30. Molitch ME, Russell EJ. The pituitary incidentaloma. Ann Intern Med 1990; 112:925-931.
31. Soule SG, Farhi J, Conway GS, et al. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Clin Endocrinol 1996; 53:711-716.
32. Petrovich Z, Jozsef G, Yu C, Apuzzo ML. Radiotherapy and stereotactic radiosurgery for pituitary tumors. Neurosurg Clin North Am 2003; 14:147-166. This study reviews the merits of conventional external beam radiotherapy and novel stereotactic techniques.
33. Fahlbusch R, Thapar K. New developments in pituitary surgical techniques. In: Davis JRE, editor. Bailliere's best practice and research, clinical endocrinology and metabolism, Vol 13(3) Pituitary tumours. London: Bailliere Tindall; 1999. pp. 471-484.
34. Wass JAH. Pituitary surgery. In: Sheppard MC, Stewart PM, editors. Pituitary disease. Dordrecht: Kluwer; 2002. pp. 221-231.
35. Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinaemia. J Clin Endocrinol Metab 1992; 75:698-703.
36. Molitch ME. Diagnosis and treatment of prolactinomas. Adv Intern Med 1999; 44:117-153.
37. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13:220-240.
38. Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 2004; 89:1704-1711. This is a valuable study of the effects of treatment of men with prolactinomas, who usually demonstrate less recovery of gonadal function than women.
39. Webster J, Piscitelli G, Olli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinaemic amenorrhoea. Cabergoline Comparative Study Group. N Engl J Med 1994; 331:904-909.
40. Verhelst J, Froud AL, Touzel R, et al. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinaemia: a double-blind study. Acta Endocrinol 1991; 125:385-391.
41. Giusti M, Porcella E, Carraro A, et al. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinaemic patients. J Endocrinol Invest 1994; 17:51-57.
42. Touraine P, Deneux C, Plu-Bureau G, et al. Hormonal replacement therapy in menopausal women with a history of hyperprolactinaemia. J Endocrinol Invest 1998; 21:732-736.
43. Testa G, Vegetti W, Motta T, et al. Two-year treatment with oral contraceptives in hyperprolactinaemic patients. Contraception 1998; 58:69-73.
44. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003; 182:199-204. This paper reviews the value of newer antipsychotic drugs that cause less disturbance of prolactin secretion.
45. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004; 65:57-61. This study reports a direct comparison among a series of drugs used for schizophrenia, and identifies drugs that do not disrupt pituitary function.
46. Karagianis JL, Baksh A. High-dose olanzapine and prolactin levels. J Clin Psychiatry 2003; 64:1192-1194. This study reports that even high-dose olanzapine appears not to stimulate prolactin secretion.
47. Goffin V, Bernichstein S, Kayser C, Kelly PA. Development of new prolactin analogs acting as pure prolactin receptor antagonists. Pituitary 2003; 6:89-95. A review of the biology of prolactin antagonists, which may have useful antiproliferative effects, with possible value in the treatment of breast cancer.
48. Molitch ME. Pituitary diseases in pregnancy. Semin Perinatol 1998; 22:457-470.
49. Moriondo P, Travaglini P, Nissim M, et al. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 1985; 60:764-772.
50. Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol 1996; 45:299-303.
51. Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003; 349:2023-2033. This paper reports that successfully treated prolactinomas frequently remain in remission after cessation of dopamine agonist therapy. Patients need to be carefully selected and followed up, but the results suggest that drug therapy may not need to be life-long.